Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure

Objective:Drug-resistance mutations are routinely detected using standard Sanger sequencing, which does not detect minor variants with a frequency below 20%. The impact of detecting minor variants generated by ultra-deep sequencing (UDS) on HIV drug-resistance interpretations has not yet been studied. Design:Fifty HIV-1 patients who experienced virological failure were included in this retrospective study. Methods:The HIV-1 UDS protocol allowed the detection and quantification of HIV-1 protease and reverse transcriptase variants related to genotypes A, B, C, F and G. DeepChek-HIV simplified drug-resistance interpretation software was used to compare Sanger sequencing and UDS. Results:The total time required for the UDS protocol was found to be approximately three times longer than Sanger sequencing with equivalent reagent costs. UDS detected all of the mutations found by population sequencing and identified additional resistance variants in all patients. An analysis of drug resistance revealed a total of 643 and 224 clinically relevant mutations by UDS and Sanger sequencing, respectively. Three resistance mutations with more than 20% prevalence were detected solely by UDS: A98S (23%), E138A (21%) and V179I (25%). A significant difference in the drug-resistance interpretations for 19 antiretroviral drugs was observed between the UDS and Sanger sequencing methods. Y181C and T215Y were the most frequent mutations associated with interpretation differences. Conclusion:A combination of UDS and DeepChek software for the interpretation of drug resistance results would help clinicians provide suitable treatments. A cut-off of 1% allowed a better characterization of the viral population by identifying additional resistance mutations and improving the drug-resistance interpretation.

[1]  D. Olive,et al.  Clinical and analytical relevance of NNRTIs minority mutations on viral failure in HIV‐1 infected patients , 2014, Journal of medical virology.

[2]  Rolf Kaiser,et al.  Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response , 2013, PloS one.

[3]  K. Metzner,et al.  Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. , 2013, Journal of Infectious Diseases.

[4]  R. Shafer,et al.  Update of the drug resistance mutations in HIV-1: March 2013. , 2013, Topics in antiviral medicine.

[5]  S. Sirivichayakul,et al.  Comparison of predicted susceptibility between genotype and virtual phenotype HIV drug resistance interpretation systems among treatment-naive HIV-infected patients in Asia: TASER-M cohort analysis , 2012, BMC Research Notes.

[6]  P. Massip,et al.  Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[7]  R. Kagan,et al.  A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-Experienced Patients , 2012, PloS one.

[8]  D. O’Connor,et al.  Low-Cost Ultra-Wide Genotyping Using Roche/454 Pyrosequencing for Surveillance of HIV Drug Resistance , 2012, PloS one.

[9]  M. Danzer,et al.  Human immunodeficiency virus type 1 drug resistance testing: Evaluation of a new ultra-deep sequencing-based protocol and comparison with the TRUGENE HIV-1 Genotyping Kit. , 2011, Journal of virological methods.

[10]  Niko Beerenwinkel,et al.  Ultra-deep sequencing for the analysis of viral populations. , 2011, Current opinion in virology.

[11]  J. Aerssens,et al.  Minor variant detection in amplicons using 454 massive parallel pyrosequencing: experiences and considerations for successful applications. , 2011, BioTechniques.

[12]  Jun Yong Choi,et al.  Detection of Minority Resistance during Early HIV-1 Infection: Natural Variation and Spurious Detection rather than Transmission and Evolution of Multiple Viral Variants , 2011, Journal of Virology.

[13]  Jeffrey N. Martin,et al.  Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy , 2010, Journal of acquired immune deficiency syndromes.

[14]  S. Hammer,et al.  Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. , 2010, The Journal of infectious diseases.

[15]  R. Paredes,et al.  Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. , 2010, The Journal of infectious diseases.

[16]  Kevin Dieckhaus,et al.  Low-Abundance HIV Drug-Resistant Viral Variants in Treatment-Experienced Persons Correlate with Historical Antiretroviral Use , 2009, PloS one.

[17]  Gregory S Turenchalk,et al.  Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. , 2009, The Journal of infectious diseases.

[18]  A. Lazzarin,et al.  Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies , 2009, AIDS.

[19]  K. Metzner,et al.  Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  P. Mee,et al.  Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa , 2008, AIDS.

[21]  Tommy F. Liu,et al.  Minority Human Immunodeficiency Virus Type 1 Variants in Antiretroviral-Naive Persons with Reverse Transcriptase Codon 215 Revertant Mutations , 2008, Journal of Virology.

[22]  Michael Monsour,et al.  Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.

[23]  Mark Myatt,et al.  Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment , 2008, Antiviral therapy.

[24]  B. Schmidt,et al.  Differences of nine drug resistance interpretation systems in predicting short-term therapy outcomes of treatment-experienced HIV-1 infected patients: a retrospective observational cohort study. , 2007, European journal of medical research.

[25]  J. Eshleman,et al.  Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. , 2006, The Journal of molecular diagnostics : JMD.

[26]  A. Vandamme,et al.  Algorithms for the interpretation of HIV-1 genotypic drug resistance information. , 2006, Antiviral research.

[27]  Lynn Morris,et al.  Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent , 2006, Antimicrobial Agents and Chemotherapy.

[28]  L. Pérez-Alvárez,et al.  Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[29]  John W. Mellors,et al.  Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis , 2005, Journal of Clinical Microbiology.

[30]  F. Heinz,et al.  Comparison of virtual phenotype and HIV‐SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains , 2002, HIV medicine.

[31]  S. Staszewski,et al.  Comparison of Nine Resistance Interpretation Systems for HIV-1 Genotyping , 2002, Antiviral therapy.

[32]  B. Larder,et al.  Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing , 1993, Nature.